In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eurofins Scientific

https://www.eurofins.com/

Latest From Eurofins Scientific

Rising Price Complaints Prompt Renewed China Probes

Pfizer is reportedly among a clutch of drug makers said to have been summoned to provide information in China's latest investigation of drug prices, which has apparently been prompted by rising public complaints over medicine costs. Chinese regulators could also impose hefty new fines on multinationals if they refuse to provide relevant materials or information, under a draft of revised antitrust regulation.

BioPharmaceutical China

Erye Deal To Boost Fosun’s Anti-Infective Interests

Shanghai Fosun Pharmaceutical Group is continuing on an acquisitive streak with a plan to buy an initial 65% stake in Suzhou Erye Pharmaceutical, and may eventually fully acquire the company in a deal worth nearly $250 million in total.

BioPharmaceutical China

United Family Healthcare’s David Rutstein On Developing China’s Private Health Sector: An Interview With PharmAsia News (Part 2 of 2)

The vice president for Medical Affairs discusses the recent Chindex Internationa merger, the challenges and opportunities that the company faces to meet the need for more private health care, as the central government ramps up spending and attitudes toward health insurance and medical incentives change.

BioPharmaceutical China

United Family Healthcare’s David Rutstein On Developing China’s Private Health Sector: An Interview With PharmAsia News (Part 1 of 2)

The vice president for Medical Affairs discusses the recent Chindex International merger, the challenges and opportunities that the company faces to meet the need for more private health care, as the central government ramps up spending and attitudes toward health insurance and medical incentives change.

BioPharmaceutical China
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Services
  • Other Names / Subsidiaries
    • Eurofins GSC Lux SARL
    • Viracor-IBT Laboratories, Inc.
UsernamePublicRestriction

Register